Predictors of Opioid-Related Death During Methadone Therapy

Journal of Substance Abuse Treatment

Volumn 57, Issue , 2015, Pages 30-35

  Leece, Pamela ^a   Cavacuiti, Christopher ^b   Macdonald, Erin M ^c   Gomes, Tara ^a,c,d,e   Kahan, Meldon ^b   Srivastava, Anita ^f   Steele, Leah ^b,c   Luo, Jin ^c   Mamdani, Muhammad M ^c,d,e,g,h   Juurlink, David N ^c,e,i,j  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST JOSEPH S HEALTH CENTRE   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h KING SAUD UNIVERSITY   (Saudi Arabia)

ⁱ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^j Institute of Clinical Evaluative Sciences   (Canada)

more..

Author keywords

Methadone; Mortality; Opioids; Substance use disorder

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; METHADONE; NEUROLEPTIC AGENT; OPIATE; NARCOTIC ANALGESIC AGENT;

ADULT; ALCOHOL USE DISORDER; ARTICLE; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEATH; FEMALE; HEALTH CARE; HEALTH CARE UTILIZATION; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MINDFULNESS; MOOD DISORDER; MORTALITY; OPIATE ADDICTION; PRIORITY JOURNAL; CASE CONTROL STUDY; EPIDEMIOLOGY; MIDDLE AGED; ONTARIO; OPIATE SUBSTITUTION TREATMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; ANALGESICS, OPIOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; ONTARIO; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RISK FACTORS;

EID: 84940598713     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2015.04.008     Document Type: Article

References (51)

1. Bernard J.-P., Havnes I., Slørdal L., Waal H., Mørland J., Khiabani H.Z. Methadone-related deaths in Norway. Forensic Science International 2013, 224(1-3):111-116. 10.1016/j.forsciint.2012.11.010.
2. Brådvik L., Berglund M., Frank A., Lindgren A., Löwenhielm P. Number of addictive substances used related to increased risk of unnatural death: A combined medico-legal and case-record study. BMC Psychiatry 2009, 9:48. 10.1186/1471-244X-9-48.
3. Brugal M.T., Domingo-Salvany A., Puig R., Barrio G., García de Olalla P., de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction (Abingdon, England) 2005, 100(7):981-989. 10.1111/j.1360-0443.2005.01089.x.
4. Caplehorn J.R., Drummer O.H. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved. The Medical Journal of Australia 1999, 170(3):104-109. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10065120).
5. Chan G.M., Stajic M., Marker E.K., Hoffman R.S., Nelson L.S. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: Analysis of medical examiner data. Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine 2006, 13(5):543-547. 10.1197/j.aem.2005.12.011.
6. Chou R., Cruciani R.A., Fiellin D.A., Compton P., Farrar J.T., Haigney M.C., et al. Methadone safety: a clinical practice guideline from the American pain society and college on problems of drug dependence, in collaboration with the heart rhythm society. The Journal of Pain : Official Journal of the American Pain Society 2014, 15(4):321-337. 10.1016/j.jpain.2014.01.494.
7. Chou R., Weimer M.B., Dana T. Methadone overdose and cardiac arrhythmia potential: Findings from a review of the evidence for an American pain society and college on problems of drug dependence clinical practice guideline. The Journal of Pain : Official Journal of the American Pain Society 2014, 15(4):338-365. 10.1016/j.jpain.2014.01.495.
8. Chugh S.S., Socoteanu C., Reinier K., Waltz J., Jui J., Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. The American Journal of Medicine 2008, 121(1):66-71. 10.1016/j.amjmed.2007.10.009.
9. Clausen T., Waal H., Thoresen M., Gossop M. Mortality among opiate users: Opioid maintenance therapy, age and causes of death. Addiction (Abingdon, England) 2009, 104(8):1356-1362. 10.1111/j.1360-0443.2009.02570.x.
10. Cousins G., Teljeur C., Motterlini N., McCowan C., Dimitrov B.D., Fahey T. Risk of drug-related mortality during periods of transition in methadone maintenance treatment: A cohort study. Journal of Substance Abuse Treatment 2011, 41(3):252-260. 10.1016/j.jsat.2011.05.001.
11. Darke S., Kaye S., Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction (Abingdon, England) 2006, 101(9):1299-1305. 10.1111/j.1360-0443.2006.01495.x.
12. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20years: Risk factors and lives saved. Drug and Alcohol Dependence 2009, 105(1-2):9-15. 10.1016/j.drugalcdep.2009.05.021.
13. Dhalla I.A., Mamdani M.M., Gomes T., Juurlink D.N. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Canadian Family Physician Médecin de Famille Canadien 2011, 57(3):e92-e96. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3056701&tool=pmcentrez&rendertype=abstract).
14. Dhalla I.A., Mamdani M.M., Sivilotti M.L.A., Kopp A., Qureshi O., Juurlink D.N. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ : Canadian Medical Association Journal=Journal de l'Association Medicale Canadienne 2009, 181(12):891-896. 10.1503/cmaj.090784.
15. Esteban J., Gimeno C., Barril J., Aragonés A., Climent J.M., de la Cruz Pellín M. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug and Alcohol Dependence 2003, 70(2):193-200. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12732413).
16. European Monitoring Centre for Drugs and Drug Addiction Drug-related deaths and mortality - An overview of the methods and definitions used 2009, 1. (Retrieved from http://www.emcdda.europa.eu/stats09/drd/methods).
17. Fischer B., Nakamura N., Rush B., Rehm J., Urbanoski K. Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. Drug and Alcohol Dependence 2010, 109(1-3):257-260. 10.1016/j.drugalcdep.2010.02.001.
18. Gibson A., Degenhardt L., Mattick R.P., Ali R., White J., O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction (Abingdon, England) 2008, 103(3):462-468. 10.1111/j.1360-0443.2007.02090.x.
19. Gomes T., Juurlink D.N., Dhalla I.A., Mailis-Gagnon A., Paterson J.M., Mamdani M.M. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Medicine : A Peer-Reviewed, Independent, Open-Access Journal 2011, 5(1):e13-e22. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3205807&tool=pmcentrez&rendertype=abstract).
20. Gossop M., Stewart D., Treacy S., Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction (Abingdon, England) 2002, 97(1):39-47. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11895269).
21. Hart A.W. Report of the Methadone Maintenance Treatment Practices Task Force 2007, 1-146. Ontario, Canada. (Retrieved from http://www.health.gov.on.ca/en/common/ministry/publications/reports/methadone_taskforce/methadone_taskforce.pdf).
22. Heinemann A., Iwersen-Bergmann S., Stein S., Schmoldt A., Püschel K. Methadone-related fatalities in Hamburg 1990-1999: Implications for quality standards in maintenance treatment?. Forensic Science International 2000, 113(1-3):449-455. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10978661).
23. Hillier W. Methadone Program: Methadone Maintenance Treatment Program Standards and Clinical Guidelines 2011, (Retrieved from https://www.cpso.on.ca/uploadedFiles/members/MMT-Guidelines.pdf).
24. Huang C.L.-C., Lee C.W. Factors associated with mortality among heroin users after seeking treatment with methadone: A population-based cohort study in Taiwan. Journal of Substance Abuse Treatment 2013, 44(3):295-300. 10.1016/j.jsat.2012.08.003.
25. Juurlink D.N., Gomes T., Lipscombe L.L., Austin P.C., Hux J.E., Mamdani M.M. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population based cohort study. BMJ (Clinical Research Ed.) 2009, 339:b2942. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2728804&tool=pmcentrez&rendertype=abstract).
26. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. The New England Journal of Medicine 2004, 351(6):543-551. 10.1056/NEJMoa040135.
27. Kapur B.M., Hutson J.R., Chibber T., Luk A., Selby P. Methadone: a review of drug-drug and pathophysiological interactions. Critical Reviews in Clinical Laboratory Sciences 2011, 48(4):171-195. 10.3109/10408363.2011.620601.
28. Langendam M.W., van Brussel G.H., Coutinho R.A., van Ameijden E.J. The impact of harm-reduction-based methadone treatment on mortality among heroin users. American Journal of Public Health 2001, 91(5):774-780. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1446673&tool=pmcentrez&rendertype=abstract).
29. Levy A.R., O'Brien B.J., Sellors C., Grootendorst P., Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. The Canadian Journal of Clinical Pharmacology=Journal Canadien de Pharmacologie Clinique 2003, 10(2):67-71. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12879144).
30. Luce J., Strike C. A cross Canada scan of methadone maintenance treatment policy developments 2011, (Retrieved from http://canadianharmreduction.com/node/1975).
31. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews 2009, 3:CD002209. 10.1002/14651858.CD002209.pub2.
32. McCowan C., Kidd B., Fahey T. Factors associated with mortality in Scottish patients receiving methadone in primary care: Retrospective cohort study. BMJ (Clinical Research Ed.) 2009, 338:b2225. (Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3273784&tool=pmcentrez&rendertype=abstract).
33. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., Hawker G.A., Gunraj N., Austin P.C., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA : The Journal of the American Medical Association 2011, 305(8):783-789. 10.1001/jama.2011.190.
34. Paulozzi L.J., Logan J.E., Hall A.J., McKinstry E., Kaplan J.A., Crosby A.E. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction (Abingdon, England) 2009, 104(9):1541-1548. 10.1111/j.1360-0443.2009.02650.x.
35. Peles E., Schreiber S., Adelson M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug and Alcohol Dependence 2010, 107(2-3):141-148. 10.1016/j.drugalcdep.2009.09.013.
36. Perry A.E., Neilson M., Martyn-St James M., Glanville J.M., McCool R., Duffy S., et al. Pharmacological interventions for drug-using offenders. The Cochrane Database of Systematic Reviews 2013, 12:CD010862. 10.1002/14651858.CD010862.
37. Pilgrim J.L., McDonough M., Drummer O.H. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. Forensic Science International 2013, 226(1-3):216-222. 10.1016/j.forsciint.2013.01.028.
38. Schwartz R.P., Gryczynski J., O'Grady K.E., Sharfstein J.M., Warren G., Olsen Y., et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. American Journal of Public Health 2013, 103(5):917-922. 10.2105/AJPH.2012.301049.
39. Srivastava A., Kahan M. Methadone induction doses: Are our current practices safe?. Journal of Addictive Diseases 2006, 25(3):5-13. 10.1300/J069v25n03_02.
40. Srivastava A., Kahan M., Ross S. The effect of methadone maintenance treatment on alcohol consumption: A systematic review. Journal of Substance Abuse Treatment 2008, 34(2):215-223. 10.1016/j.jsat.2007.04.001.
41. Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality The N-SSATS Report: Trends in the use of methadone and buprenorphine at substance abuse treatment facilities: 2003 to 2011. Rockville, MD 2013.
42. The DAWN Report Methadone-involved deaths in 8 metropolitan areas: 1997-2001 2004, 1-4.
43. US Department of Health and Services Methadone mortality : A 2010 reassessment 2010, 1-46. (Retrieved from http://www.dpt.samhsa.gov/pdf/methadone_mortality_data_2010.pdf).
44. Vital signs: Risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR. Morbidity and Mortality Weekly Report 2012, 61(26):493-497. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22763888).
45. Weimer M.B., Chou R. Research gaps on methadone harms and comparative harms: Findings from a review of the evidence for an American pain society and college on problems of drug dependence clinical practice guideline. The Journal of Pain : Official Journal of the American Pain Society 2014, 15(4):366-376. 10.1016/j.jpain.2014.01.496.
46. Weimer M.B., Korthuis P.T., Behonick G.S., Wunsch M.J. The source of methadone in overdose deaths in Western Virginia in 2004. Journal of Addiction Medicine 2011, 5(3):188-202. 10.1097/ADM.0b013e318211c56a.
47. Weiner Jonathan P. The John Hopkins University Bloomberg School of Public Health, Health Services Research & Development Center. The John Hopkins ACG® Case-Mix System Version 6.0 Release Notes 2003.
48. Wikner B.N., Ohman I., Seldén T., Druid H., Brandt L., Kieler H. Opioid-related mortality and filled prescriptions for buprenorphine and methadone. Drug and Alcohol Review 2014, 33(5):491-498. 10.1111/dar.12143.
49. World Health Organization WHO drug information. WHO Drug Information 2005, 19(3). (Retrieved from http://apps.who.int/medicinedocs/index/assoc/s14243e/s14243e.pdf).
50. Zador D., Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction (Abingdon, England) 2000, 95(1):77-84. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10723832).
51. Zanis D.A., Woody G.E. One-year mortality rates following methadone treatment discharge. Drug and Alcohol Dependence 1998, 52(3):257-260. (Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9839152).